financetom
Business
financetom
/
Business
/
GR Silver Mining Drills Wide Silver Intercepts at San Marcial
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
GR Silver Mining Drills Wide Silver Intercepts at San Marcial
Aug 21, 2025 5:56 AM

08:20 AM EDT, 08/21/2025 (MT Newswires) -- GR Silver Mining ( GRSLF ) on Thursday provided drilling results from the ongoing Step-Out Drilling Program adjacent to the 2023 NI 43-101 mineral resource at the San Marcial Area, Plomosas project, in Sinaloa, Mexico.

The company said drilling at hole SMS25-08 successfully discovered a new high-grade gold-silver epithermal vein and intersected a wide, predominantly silver-mineralized intercept hosted in hydrothermal breccia. Hole SMS25-07A intersected multiple zones of wide silver mineralization at shallow depth.

It said hole SMS25-08 was drilled to test the down-dip continuity of silver mineralization 45 metres below historical trench results, targeting a perpendicular orientation to the northeast structures and their intersections with northwest-oriented regional structures. The presence of mineralization at these intersections oriented towards the northeast represents a "potential opportunity for resource expansion at this target."

"Each batch of drill results received from the step-out drilling program increases the prospective scale of the San Marcial Area, potentially unlocking a much larger resource," said GR Silver Mining ( GRSLF ) Chief Executive Marcio Fonseca. "The continuity of high silver grades and broad widths of predominant silver mineralization encountered at shallow depths, as revealed by the step-out drilling, supports the opportunity to continue drilling and expanding resources in the vicinity of the San Marcial Resource Area."

"We await additional assay results now from the SE Deep Extension target, which we believe will potentially lead to an extension of mineralization below existing resource boundaries," said Fonseca.

Shares of the company closed up 6.7% to $0.16 on Wednesday on the TSX Venture Exchange.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Yatsen Reports Q2 Adjusted Earnings, Higher Revenue; Q3 Sales Outlook Set
Yatsen Reports Q2 Adjusted Earnings, Higher Revenue; Q3 Sales Outlook Set
Aug 21, 2025
05:25 AM EDT, 08/21/2025 (MT Newswires) -- Yatsen Holding ( YSG ) reported Q2 non-GAAP earnings Thursday of 0.13 Chinese renminbi ($0.02) per diluted American depositary share, swinging from a loss of 0.67 renminbi a year earlier. Analyst estimates were not readily available for comparison. Net revenue for the quarter ended June 30 was 1.09 billion renminbi, compared with 794.5...
Chinese cosmetics firm Yatsen Q2 revenue rises
Chinese cosmetics firm Yatsen Q2 revenue rises
Aug 21, 2025
Overview * Yatsen Q2 2025 rev rises 36.8% yr/yr to RMB1.09 bln * Net loss narrows 77.2% to RMB19.5 mln, non-GAAP net income positive * Gross margin improves to 78.3%, driven by higher-margin product sales Outlook * Yatsen expects Q3 2025 net revenues between RMB778.6 mln and RMB880.1 mln * Company forecasts Q3 2025 revenue growth of 15% to 30%...
Johnson & Johnson to invest $2 billion to boost US manufacturing as drug tariffs loom
Johnson & Johnson to invest $2 billion to boost US manufacturing as drug tariffs loom
Aug 21, 2025
(Reuters) -Johnson & Johnson ( JNJ ) committed to invest $2 billion in North Carolina on Thursday to expand the drugmaker's U.S. manufacturing presence as potential drug import duties from President Donald Trump's administration loom. J&J said it plans to build a new facility at Tokyo-based Fujifilm Diosynth's manufacturing site in Holly Springs, North Carolina, over the next 10 years....
Alvotech Says European Commission Approved Mynzepli to Treat Retinal Diseases
Alvotech Says European Commission Approved Mynzepli to Treat Retinal Diseases
Aug 21, 2025
05:29 AM EDT, 08/21/2025 (MT Newswires) -- Alvotech ( ALVO ) and UK-based Advanz Pharma said Thursday that their Mynzepli fusion protein was approved by the European Commission to treat retinal diseases, including neovascular age-related macular degeneration. The companies said the approval was based on non-clinical and clinical similarity data, which included a confirmatory efficacy study comparing Mynzepli with Bayer's...
Copyright 2023-2025 - www.financetom.com All Rights Reserved